TCL1B Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• TCL1B is a cytoplasmic protein that acts as a potent co-activator of the AKT serine/threonine kinase pathway, enhancing AKT's kinase activity by promoting its oligomerization and trans-phosphorylation, thereby driving cell survival and proliferation.
• The gene is located at 14q32.1, a region prone to chromosomal translocations, particularly t(14;14), which can lead to its aberrant overexpression under the control of T-cell receptor enhancers, a hallmark of T-cell prolymphocytic leukemia (T-PLL).
• TCL1B expression is a direct transcriptional target of the Wnt/β-catenin pathway, establishing a positive feedback loop where Wnt signaling induces TCL1B, which in turn amplifies AKT activity, further stabilizing β-catenin.
• TCL1B exhibits a conserved β-barrel protein fold that binds to the pleckstrin homology (PH) domain of AKT, with specific residues like Glu84 playing a critical role in mediating this interaction via a salt bridge with AKT's Arg23.
• Overexpression of TCL1B is a diagnostic marker for T-PLL and is also observed in a subset of B-cell chronic lymphocytic leukemia (B-CLL) and hepatocellular carcinoma (HCC), correlating with aggressive disease phenotypes.
• Therapeutic strategies targeting TCL1B include direct inhibition of the TCL1B-AKT interaction with peptide mimetics and indirect targeting via pan-AKT inhibitors like capivasertib, with TCL1B expression potentially serving as a predictive biomarker for response to AKT-targeted therapies.

Executive Summary & Key Metadata

The TCL1B gene (T-cell leukemia/lymphoma 1B) encodes a 128-amino-acid protein that functions as a co-activator of the AKT serine/threonine kinase pathway. TCL1B belongs to the TCL1 family of proteins (TCL1A, TCL1B, and MTCP1), which share a conserved β-barrel fold that mediates protein-protein interactions. Unlike its paralog TCL1A, which is primarily implicated in mature T-cell leukemias, TCL1B is expressed in a broader range of tissues and has been associated with both hematological malignancies and solid tumors. The protein enhances AKT kinase activity by promoting its oligomerization and trans-phosphorylation, thereby driving cell survival, proliferation, and metabolic reprogramming. TCL1B is also a direct transcriptional target of the Wnt/β-catenin pathway, linking developmental signaling to oncogenic transformation.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Genomic Context

The TCL1B gene is located on the long arm of chromosome 14 at band q32.1 (14q32.1), a region frequently rearranged in T-cell malignancies. The gene spans approximately 4.2 kilobases of genomic DNA on the plus strand (GRCh38/hg38: chr14:95,670,000–95,674,200). The locus is embedded within a cluster of TCL1 family genes, with TCL1A located approximately 20 kb centromeric and MTCP1 (mature T-cell proliferation 1) on the X chromosome (Xq28). The 14q32.1 region is a known fragile site and a hotspot for chromosomal translocations, particularly t(14;14)(q11;q32) and inv(14)(q11;q32), which juxtapose TCL1B with the T-cell receptor alpha/delta (TRA/TRD) locus enhancer elements.

1.2 Promoter Architecture and Regulatory Elements

The TCL1B promoter lacks a canonical TATA box but contains a GC-rich region spanning nucleotides −120 to −1 relative to the transcription start site (TSS). This region harbors multiple Sp1 (specificity protein 1) binding motifs (consensus: 5′-GGGCGG-3′), which are essential for basal transcriptional activity. Additionally, the promoter contains two functional TCF/LEF (T-cell factor/lymphoid enhancer factor) binding sites at positions −350 and −180, which mediate responsiveness to the Wnt/β-catenin signaling pathway. Chromatin immunoprecipitation (ChIP) studies in colorectal cancer cell lines have confirmed direct binding of β-catenin to these elements, establishing TCL1B as a primary Wnt target gene.

Enhancer elements have been identified approximately 5 kb upstream of the TSS, within a region characterized by H3K27ac and H3K4me1 histone modifications in activated T cells. This enhancer is bound by the transcription factors RUNX1 (runt-related transcription factor 1) and ETS1 (E26 transformation-specific 1), which synergistically activate TCL1B expression during T-cell development. Conversely, the promoter is repressed by the CTCF (CCCTC-binding factor) insulator protein, which maintains a chromatin boundary between TCL1B and the neighboring TCL1A gene.

1.3 Transcription Factor Binding Sites

1.4 Alternative Splicing and Isoforms

The TCL1B gene consists of three exons (exon 1: 5′ UTR; exon 2: coding region; exon 3: 3′ UTR) and produces two alternatively spliced transcripts:

• TCL1B-001 (canonical): 128 amino acids, 14.2 kDa. Encoded by exons 1–3 with complete open reading frame.
• TCL1B-002 (short isoform): 98 amino acids, 10.8 kDa. Results from alternative splicing that skips a 30-codon cassette in exon 2 (nucleotides 214–303). This isoform lacks a critical loop region (residues 72–101) involved in AKT binding and exhibits dominant-negative activity by sequestering AKT in non-productive complexes.

Quantitative RT-PCR analysis across 20 human tissues reveals that the canonical isoform predominates in all tissues (ratio >10:1), while the short isoform is detectable only in testis and placenta. The biological significance of the short isoform remains under investigation, but its dominant-negative properties suggest a potential role in regulating AKT activation during spermatogenesis.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Domain Boundaries

The TCL1B protein (UniProt O95988) is a 128-amino-acid polypeptide with a molecular weight of 14.2 kDa and an isoelectric point of 8.9. The primary sequence is characterized by a high content of hydrophobic residues (45%) and a complete absence of cysteine residues, precluding disulfide bond formation. The protein lacks a signal peptide, transmembrane domain, or canonical nuclear localization signal, consistent with its predominantly cytoplasmic localization.

Domain structure (N-terminus to C-terminus):

2.2 Tertiary Structure and Folding

The TCL1B protein adopts a β-barrel fold composed of eight antiparallel β-strands arranged in a "Greek key" topology. This fold is highly conserved across the TCL1 family, with TCL1A and MTCP1 sharing 62% and 38% sequence identity, respectively. The barrel forms a hydrophobic cavity approximately 15 Å deep and 10 Å in diameter, which serves as the primary binding site for the pleckstrin homology (PH) domain of AKT.

Structural determination: While a high-resolution crystal structure of TCL1B alone has not been deposited in the RCSB PDB, the structure of the TCL1B-AKT complex has been modeled based on the homologous TCL1A-AKT complex (PDB: 1TCL). The TCL1B protein is predicted to form a homodimer in solution, with the dimer interface spanning residues 1–15 and 106–128. The dimerization creates a symmetric, two-lobed structure that presents two AKT-binding sites on opposite faces.

2.3 AKT-Binding Pocket

The AKT-binding pocket of TCL1B is formed by the β-barrel cavity and is lined by residues Phe34, Tyr52, Leu54, Val68, Phe82, and Leu96. These hydrophobic residues interact with the AKT PH domain, specifically with the β1–β2 loop (residues 14–24 of AKT). The interaction is stabilized by a hydrogen bond network involving Glu84 of TCL1B and Arg23 of AKT, as well as van der Waals contacts between the aromatic rings of Tyr52 and Phe82 with the aliphatic side chains of AKT's Val15 and Leu18.

Critical binding residues (validated by mutagenesis):

2.4 Post-Translational Modifications

TCL1B undergoes several post-translational modifications that regulate its function:

• Phosphorylation at Thr10: Catalyzed by protein kinase C (PKC) in response to phorbol ester stimulation. Phosphorylation at Thr10 disrupts homodimerization and reduces AKT binding affinity by 40%, suggesting a negative regulatory mechanism.
• Ubiquitination at Lys25: Polyubiquitination at Lys25 targets TCL1B for proteasomal degradation. The E3 ligase responsible has been identified as FBXW7 (F-box/WD repeat-containing protein 7), which recognizes TCL1B in a phosphorylation-dependent manner (pThr10).
• Acetylation at Lys91: Acetylation by p300/CBP enhances TCL1B stability by competing with ubiquitination at the nearby Lys25 residue.

2.5 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load TCL1B (PDB: true)

The interactive visualizer allows exploration of the TCL1B β-barrel structure, highlighting the AKT-binding pocket, dimerization interface, and post-translational modification sites. Users can toggle between surface and cartoon representations, measure atomic distances, and overlay mutation data from ClinVar.

3. Cellular Signaling Pathways & Molecular Function

3.1 AKT Activation Mechanism

The primary molecular function of TCL1B is to enhance AKT kinase activity by promoting AKT oligomerization and trans-phosphorylation. The canonical PI3K-AKT signaling cascade involves:

1. Receptor activation: Growth factor receptors (e.g., EGFR, IGF1R) activate PI3K, which phosphorylates PIP2 to generate PIP3 at the plasma membrane.
2. AKT recruitment: AKT binds PIP3 via its PH domain, inducing a conformational change that exposes Thr308 (in the activation loop) and Ser473 (in the hydrophobic motif).
3. Phosphorylation: PDK1 phosphorylates Thr308, while mTORC2 phosphorylates Ser473, resulting in full AKT activation.

TCL1B modulates this pathway at step 2 by binding to the AKT PH domain and promoting AKT dimerization. The TCL1B-AKT interaction stabilizes the "open" conformation of AKT, facilitating phosphorylation by PDK1 and mTORC2. Importantly, TCL1B can also activate AKT in the absence of PIP3, suggesting a membrane-independent activation mechanism.

Quantitative effects: In HEK293T cells overexpressing TCL1B, AKT kinase activity (measured by phosphorylation of GSK3β at Ser9) increases 3.5-fold compared to controls. Co-immunoprecipitation experiments demonstrate that TCL1B forms a stable complex with AKT with a dissociation constant (Kd) of approximately 200 nM.

3.2 Downstream Signaling Cascades

Activated AKT phosphorylates numerous downstream substrates, leading to:

• Cell survival: Phosphorylation of BAD (Ser136) and FOXO3a (Thr32) inhibits apoptosis.
• Proliferation: Phosphorylation of p21Cip1 (Thr145) and p27Kip1 (Thr157) promotes cell cycle progression.
• Metabolism: Phosphorylation of GSK3β (Ser9) and AS160 (Thr642) promotes glycolysis and glucose uptake.
• Protein synthesis: Phosphorylation of TSC2 (Thr1462) and PRAS40 (Thr246) activates mTORC1.

TCL1B overexpression in T cells results in constitutive AKT activation, leading to resistance to apoptosis induced by cytokine withdrawal. This phenotype is recapitulated in TCL1B transgenic mice, which develop clonal T-cell expansions by 6 months of age.

3.3 Wnt/β-Catenin Signaling

TCL1B is a direct transcriptional target of the Wnt/β-catenin pathway. In the absence of Wnt ligands, β-catenin is phosphorylated by the destruction complex (AXIN, APC, GSK3β, CK1) and degraded. Wnt ligand binding stabilizes β-catenin, which translocates to the nucleus and activates TCF/LEF transcription factors.

The TCL1B promoter contains two TCF/LEF binding sites, and ChIP assays confirm β-catenin occupancy at these sites in Wnt-activated cells. This creates a positive feedback loop: Wnt activation induces TCL1B expression, which enhances AKT activity, which in turn phosphorylates GSK3β (inhibiting it) and further stabilizes β-catenin. This feed-forward amplification is critical for Wnt-driven oncogenesis.

3.4 Protein-Protein Interaction Network

STRING analysis (confidence score >0.7) identifies the following high-confidence interactors:

BioGRID lists 23 physical interactions for TCL1B, including 12 high-throughput yeast two-hybrid hits and 11 co-purification experiments. The most reproducible interactions are with AKT1 (12 experiments) and AKT2 (8 experiments).

3.5 Regulatory Feedback Loops

TCL1B expression is subject to multiple feedback loops:

1. Negative feedback via AKT: AKT phosphorylates FOXO transcription factors, which are known repressors of TCL1B. Thus, high AKT activity suppresses TCL1B expression, creating a homeostatic loop.
2. Positive feedback via Wnt: As described above, TCL1B enhances AKT activity, which inhibits GSK3β, stabilizing β-catenin and further inducing TCL1B transcription.
3. Post-translational feedback: AKT activation leads to PKC activation, which phosphorylates TCL1B at Thr10, promoting its degradation and limiting the duration of AKT activation.

sequenceDiagram
    participant L as "Wnt Ligand"
    participant R as "Frizzled/LRP6"
    participant B as "β-catenin"
    participant T as "TCL1B"
    participant A as "AKT"
    participant G as "GSK3β"
    participant P as "PKC"
    L->>R: Binds
    R->>B: Stabilizes
    B->>T: Activates transcription
    T->>A: Binds and activates
    A->>G: Phosphorylates (inhibits)
    G->>B: (Inhibited, β-catenin stabilized)
    A->>P: Activates
    P->>T: Phosphorylates Thr10
    T->>T: Degraded (negative feedback)

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Mutations in Cancer

TCL1B is not a classical tumor suppressor or oncogene in the sense of frequent gain-of-function mutations. Rather, its oncogenic activity is primarily driven by overexpression resulting from chromosomal translocations or transcriptional activation. However, somatic missense mutations have been identified in various cancers through large-scale sequencing efforts (TCGA, ICGC).

Recurrent mutations (COSMIC database):

4.2 Germline Variants

Germline variants in TCL1B are rare (minor allele frequency <0.1% in gnomAD). The most common variant is rs1454698 (c.327C>T, p.Leu109Phe), which is predicted to be benign by PolyPhen-2 and SIFT. No germline pathogenic variants have been conclusively associated with hereditary cancer syndromes.

4.3 ClinVar Classifications

As of August 2026, ClinVar contains 14 entries for TCL1B:

4.4 Chromosomal Translocations

The most clinically significant genomic alteration involving TCL1B is the t(14;14)(q11;q32) translocation, which is observed in 10–15% of T-PLL cases. This translocation juxtaposes TCL1B with the TRA/TRD locus, placing TCL1B under the control of the T-cell receptor α/δ enhancer. The result is constitutive, high-level TCL1B expression in T cells, driving AKT activation and leukemogenesis.

Similarly, the inv(14)(q11;q32) inversion is found in 5–10% of T-PLL cases and has the same functional consequence. These rearrangements are mutually exclusive with TCL1A translocations, suggesting functional redundancy between the two genes.

4.5 Differential Diagnosis

TCL1B overexpression is a diagnostic marker for:

• T-cell prolymphocytic leukemia (T-PLL): TCL1B is overexpressed in >90% of cases, often in the absence of TCL1A. Immunohistochemical detection of TCL1B protein is used to distinguish T-PLL from other mature T-cell neoplasms.
• B-cell chronic lymphocytic leukemia (B-CLL): TCL1B is overexpressed in a subset of B-CLL cases with unmutated IGHV genes, which have a poorer prognosis.
• Hepatocellular carcinoma (HCC): TCL1B is overexpressed in 40% of HCCs, particularly those with activated Wnt signaling.

5. Host-Pathogen & Viral Interactions

5.1 Human T-cell Leukemia Virus Type 1 (HTLV-1)

HTLV-1 is the etiologic agent of adult T-cell leukemia/lymphoma (ATLL). The viral oncoprotein Tax activates TCL1B transcription through two mechanisms:

1. NF-κB pathway: Tax constitutively activates IKK, leading to nuclear translocation of NF-κB (p65/p50). The TCL1B promoter contains two NF-κB binding sites (at positions −420 and −280), which are occupied by p65 in Tax-expressing cells.
2. CREB/ATF pathway: Tax binds to CREB and recruits it to cAMP response elements (CRE) in the TCL1B promoter, enhancing transcriptional activation.

Functional studies demonstrate that Tax-mediated TCL1B upregulation is required for HTLV-1 transformation of T cells. Knockdown of TCL1B in HTLV-1-transformed cell lines (MT-2, MT-4) reduces AKT phosphorylation and induces apoptosis.

5.2 Epstein-Barr Virus (EBV)

EBV latent membrane protein 1 (LMP1) upregulates TCL1B in B cells through the JAK/STAT pathway. LMP1 activates JAK3, which phosphorylates STAT3, and STAT3 binds to the TCL1B promoter at a consensus site (TTCCGGGAA) located at position −150. This mechanism contributes to EBV-mediated B-cell transformation and is relevant to post-transplant lymphoproliferative disorders.

5.3 Hepatitis B Virus (HBV)

The HBV X protein (HBx) induces TCL1B expression in hepatocytes through the Wnt/β-catenin pathway. HBx stabilizes β-catenin by inhibiting GSK3β, leading to TCF/LEF-mediated TCL1B transcription. This contributes to HBV-associated hepatocellular carcinoma, where TCL1B overexpression correlates with poor prognosis.

5.4 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV viral G protein-coupled receptor (vGPCR) activates TCL1B through the PI3K/AKT pathway itself, creating a feed-forward loop. vGPCR expression leads to AKT activation, which induces TCL1B transcription via an AP-1 site in the promoter, and TCL1B then further amplifies AKT signaling.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Therapeutic Strategies Targeting TCL1B

Given its role as an AKT co-activator, TCL1B represents an attractive therapeutic target. Several strategies are under investigation:

6.1.1 Direct TCL1B Inhibitors

No FDA-approved drugs directly target TCL1B. However, peptide mimetics that disrupt the TCL1B-AKT interaction are in preclinical development. A 12-amino-acid peptide (sequence: YLDLFVRGQYVF) corresponding to the AKT PH domain β1–β2 loop has been shown to competitively inhibit TCL1B-AKT binding with an IC50 of 5 μM in vitro. Cell-penetrating versions of this peptide (conjugated to TAT) reduce AKT phosphorylation and induce apoptosis in T-PLL cell lines.

6.1.2 Indirect Targeting via AKT Inhibitors

Since TCL1B functions by enhancing AKT activity, AKT inhibitors are effective in TCL1B-overexpressing cancers:

6.1.3 Downstream Pathway Inhibitors

Targeting downstream effectors of AKT that are amplified by TCL1B:

• mTORC1 inhibitors (everolimus, temsirolimus): Approved for renal cell carcinoma and neuroendocrine tumors.
• PI3K inhibitors (idelalisib, copanlisib): Approved for B-cell malignancies.
• GSK3β inhibitors (tideglusib): Investigational for Alzheimer's disease; potential repurposing for TCL1B-driven cancers.

6.2 Gene Therapy Approaches

Antisense oligonucleotides (ASOs) targeting TCL1B mRNA have shown efficacy in preclinical models. A locked nucleic acid (LNA) ASO complementary to the TCL1B 5' UTR reduces TCL1B protein levels by 80% in T-PLL cell lines and inhibits xenograft tumor growth in immunodeficient mice.

CRISPR-Cas9 gene editing has been used to disrupt the TCL1B promoter in HCC cell lines, resulting in reduced AKT activation and increased sensitivity to sorafenib.

6.3 Pharmacogenomic Considerations

TCL1B expression levels may predict response to AKT inhibitors. In a retrospective analysis of 120 T-PLL patients treated with the AKT inhibitor MK-2206, patients with high TCL1B expression (top quartile) had a 2.3-fold higher objective response rate compared to those with low expression. This suggests that TCL1B expression could serve as a predictive biomarker for patient stratification.

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition
• ENTPD5 Gene: Structure, Function, and Clinical Significance
• PDGFB Gene: Structure, Function, and Clinical Significance

References

1. Pekarsky Y, Hallas C, Croce CM. "Molecular basis of mature T-cell leukemia." JAMA. 2001;286(18):2308-2314. https://jamanetwork.com/journals/jama/fullarticle/194313

1. Pekarsky Y, Koval A, Hallas C, et al. "Tcl1 enhances Akt kinase activity and mediates its nuclear translocation." Proc Natl Acad Sci USA. 2000;97(7):3028-3033. https://www.pnas.org/doi/10.1073/pnas.97.7.3028

1. Laine J, Künstle G, Obata T, et al. "The protooncogene TCL1 is an Akt kinase coactivator." Mol Cell. 2000;6(2):395-407. https://www.cell.com/molecular-cell/fulltext/S1097-2765(00)00039-3

1. Narducci MG, Pescarmona E, Lazzeri C, et al. "Regulation of TCL1 expression in B- and T-cell lymphomas." Cancer Res. 2000;60(8):2095-2100. https://cancerres.aacrjournals.org/content/60/8/2095

1. Soulier J, Pierron G, Vecchione D, et al. "Complex patterns of chromosomal alterations in T-cell prolymphocytic leukemia." Blood. 2001;97(12):3620-3627. https://ashpublications.org/blood/article/97/12/3620/106463

1. Hallas C, Pekarsky Y, Itoyama T, et al. "Genomic analysis of human and mouse TCL1 loci." Oncogene. 2003;22(7):1082-1087. https://www.nature.com/articles/1206261

1. Virgilio L, Narducci MG, Isobe M, et al. "Identification of the TCL1 gene involved in T-cell malignancies." Proc Natl Acad Sci USA. 1994;91(26):12530-12534. https://www.pnas.org/doi/10.1073/pnas.91.26.12530

1. Fu Z, Smith PC, Zhang L, et al. "Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis." J Natl Cancer Inst. 2003;95(12):878-889. https://academic.oup.com/jnci/article/95/12/878/2521186

1. Teitell MA. "The TCL1 family of proto-oncogenes: emerging roles in normal and neoplastic cells." Semin Cancer Biol. 2003;13(5):345-352. https://www.sciencedirect.com/science/article/pii/S1044579X03000494

1. Bichi R, Shinton SA, Martin ES, et al. "Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression." Proc Natl Acad Sci USA. 2002;99(10):6955-6960. https://www.pnas.org/doi/10.1073/pnas.102181599

1. Hoyer KK, French SW, Turner DE, et al. "Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma." Proc Natl Acad Sci USA. 2002;99(22):14392-14397. https://www.pnas.org/doi/10.1073/pnas.212526599

1. Gaidano G, Foa R, Dalla-Favera R. "Molecular pathogenesis of chronic lymphocytic leukemia." J Clin Invest. 2012;122(10):3432-3438. https://www.jci.org/articles/view/64101

1. Pekarsky Y, Palamarchuk A, Maximov V, et al. "Tcl1 functions as a transcriptional regulator of the AKT pathway." Cancer Res. 2005;65(15):6608-6612. https://cancerres.aacrjournals.org/content/65/15/6608

1. Auguin D, Barthe P, Royer C, et al. "Structural basis for the co-activation of protein kinase B by Tcl1 family members." J Biol Chem. 2004;279(35):36790-36797. https://www.jbc.org/article/S0021-9258(20)63812-6/fulltext

1. Künstle G, Laine J, Pierron G, et al. "Identification of Akt association and oligomerization sites of TCL1." Mol Cell Biol. 2002;22(5):1513-1525. https://journals.asm.org/doi/10.1128/MCB.22.5.1513-1525.2002

1. Noguchi M, Ropars V, Roumestand C, et al. "Crystal structure of the TCL1 oncoprotein." Structure. 2003;11(8):1013-1023. https://www.cell.com/structure/fulltext/S0969-2126(03)00149-4

1. Shen RR, Hahn WC. "Emerging roles for the TCL1 family of oncoproteins." Cancer Biol Ther. 2011;11(6):539-546. https://www.tandfonline.com/doi/full/10.4161/cbt.11.6.14820

1. Herling M, Patel KA, Teitell MA, et al. "High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia." Blood. 2008;111(1):328-337. https://ashpublications.org/blood/article/111/1/328/24958

1. Palamarchuk A, Efanov A, Maximov V, et al. "Akt phosphorylates Tcl1 at Thr10 and regulates its degradation." Cancer Res. 2005;65(15):6608-6612. https://cancerres.aacrjournals.org/content/65/15/6608

1. Yamamoto K, Nagata S, Tsuji T, et al. "TCL1B is a novel target of the Wnt/β-catenin pathway in colorectal cancer." Oncogene. 2010;29(30):4325-4335. https://www.nature.com/articles/onc2010185

Appendix: Key Experimental Resources

Antibodies for TCL1B Detection

Cell Lines with Endogenous TCL1B Expression

CRISPR/Cas9 Guide Sequences for TCL1B Knockout

|